肿瘤细胞治疗研究
英文原题：Designing immunity with cytokines: A logic-based framework for programmable CAR therapies.
这些进展共同将细胞免疫治疗重新定义为一种细胞因子引导的、可编程的免疫生态系统，为不仅针对效力、还针对安全性、持久性和广泛临床整合而设计的疗法提供了概念路线图。
过继细胞免疫治疗已改变癌症治疗格局，嵌合抗原受体（CAR）T细胞在血液系统恶性肿瘤中实现了前所未有的缓解。然而，受抗原逃逸、恶劣微环境和危及生命的毒性限制，其向实体瘤的转化仍然有限。细胞因子和趋化因子是这些障碍的关键因素，影响细胞迁移、持久性和毒性，因此需要通过工程化手段加以调控。本综述提出首个统一的五层框架——识别、导航、安全、持久性和转化——以细胞因子及趋化因子逻辑组织CAR工程。创新策略包括用于应对异质性的双靶点和逻辑门控CAR；增强浸润的缺氧及趋化因子响应回路；用于减轻IL-6/IL-1驱动细胞因子风暴的诱导型安全开关；以及用于延长持久性的IL-7/IL-15支持。CAR逻辑也已拓展至NK细胞和巨噬细胞，将适应性免疫记忆与先天细胞毒性及基质重塑相结合；iPSC来源效应细胞则有望实现规模化、标准化生产。总体而言，这些进展将细胞免疫治疗重新界定为由细胞因子引导、可编程的免疫生态系统，并为开发兼具效力、安全性、持久性及广泛临床整合能力的疗法提供概念路线图。
Adoptive cellular immunotherapy has transformed cancer care, with chimeric antigen receptor (CAR) T cells achieving unprecedented remission in hematologic malignancies. Yet solid tumor translation remains limited by antigen escape, hostile microenvironments, and life-threatening toxicities. Cytokines and chemokines are central to these barriers, shaping trafficking, persistence, and toxicity in ways that demand engineered solutions. This review introduces the first unified five-layer framework-Recognition, Navigation, Safety, Persistence, and Translation-that organizes CAR engineering through cytokine and chemokine logic. Innovations include dual-target and logic-gated CARs to counter heterogeneity, hypoxia- and chemokine-responsive circuits to enhance infiltration, inducible safety switches to mitigate IL-6/IL-1 -driven cytokine storm, and IL-7/IL-15 support to extend persistence. Beyond T cells, CAR logic is now ported into NK cells and macrophages, complementing adaptive memory with innate cytotoxicity and stromal remodeling, while iPSC-derived effectors offer scalable, standardized production. Together, these advances reframe cellular immunotherapy as a cytokine-guided, programmable immune ecosystem, providing a conceptual roadmap for therapies engineered not only for potency but also for safety, durability, and broad clinical integration.
MEMBER ACCOUNT
登录成功会直接打开下一页。
